#ARWR hashtag - Bluesky

1 week ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RACE, #ARWR, #UWMC, #CX, #BMRN

#OptionFlow #OptionsTrading #Trading

1 1 1 0

1 week ago

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CRCL, #RACE, #TSM, #UWMC, #ARWR

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia Arrowhead Pharmaceuticals (NASDAQ: ARWR) has dosed the first subjects in a Phase 1/2a study of ARO-DIMER-PA, described as the first clinical RNAi candidate designed to silence two genes with one molecule (PCSK9 and APOC3) using Arrowhead's TRiM™ platform. Preclinical data in hyperlipidemic nonhuman primates showed potent lowering of PCSK9 and APOC3 and reductions in non-HDL cholesterol, LDL-C, and triglycerides. The study advances Arrowhead's cardiometabolic RNAi portfolio alongside approved REDEMPLO and ongoing programs.

2 months ago

#ARWR Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

www.stocktitan.net/news/ARWR/arrowhead-phar...

0 0 0 0

@nasdaq.activitypub.awakari.com.ap.brid.gy

2 months ago

JUST IN: ( NASDAQ: #ARWR ) Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is a Stock Spotlight on 1/13

0 0 0 0

Nasdaq

2 months ago

Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? | The Motley Fool Arrowhead Pharmaceuticals, a leader in RNAi therapeutics, reported a significant insider sale amid a year of exceptional stock gains.

#ARWR #43dab625-0cb5-4da6-b94b-3a5c24ad8672 #coveragefilings

Origin | Interest | Match

0 0 0 0

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants Arrowhead Pharmaceuticals, Inc. today announced the pricing of its concurrent public offerings of $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 and 3,100,776 shares of common stock, at a public offering price of $64.50 per share. The offering size of the note offering was increased from the previously announced...

2 months ago

#ARWR Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/ARWR/arrowhead-phar...

0 0 0 0

2 months ago

News; ( NASDAQ: #ARWR ) Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is a Stock Spotlight on 1/7

0 0 0 0

@zackssmallcap.bsky.social

2 months ago

News; ( NASDAQ: #ARWR ) Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

0 0 0 0

Zacks Small Cap Research

2 months ago

#ARWR: Encouraging Early Data for Obesity Programs… buff.ly/9N4Bfqx

0 0 0 0

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced NMPA approval of REDEMPLO (plozasiran) for reducing triglyceride levels in adults with familial chylomicronemia syndrome (FCS) in China on January 7, 2026.Under an agreement with Sanofi, Sanofi will market REDEMPLO in Greater China and the NMPA approval triggers a $10 million milestone payment to Arrowhead subsidiary Visirna Therapeutics. This is REDEMPLO’s third regulatory approval following approvals by the U.S. FDA and Health Canada. REDEMPLO is a siRNA therapy administered by subcutaneous injection once every three months.

2 months ago

#ARWR Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

www.stocktitan.net/news/ARWR/arrowhead-phar...

0 0 0 0

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced proposed public offerings of $500 million aggregate principal amount of convertible senior notes due January 15, 2032 and $200 million of common stock, each with 30-day underwriter overallotment options of $75 million and $30 million, respectively.Notes will be senior unsecured, accrue interest semi‑annually, be convertible in specified circumstances, and may be redeemable for cash on or after January 16, 2029. Arrowhead intends to use proceeds for capped call hedges, general corporate purposes, R&D, clinical trials, commercialization preparation and possible prepayment of credit facility loans.

2 months ago

#ARWR Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

www.stocktitan.net/news/ARWR/arrowhead-phar...

0 0 0 0

2 months ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ARWR, #FIGR, #IREN, #ALT, #FFAI

#OptionFlow #OptionsTrading #Trading

0 0 0 0

2 months ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #BMNR 47% OTM
2. #ARWR 29% OTM
3. #FIGR 25% OTM
4. #IREN 23% OTM
5. #FFAI 22% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that Health Canada issued a Notice of Compliance authorizing REDEMPLO (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) for whom standard therapies are inadequate.The approval is based on Phase 3 PALISADE data showing a median triglyceride change of -80% on 25 mg REDEMPLO versus -17% for pooled placebo over 12 months, and a lower numerical incidence of acute pancreatitis; common adverse reactions (≥15%) included hyperglycemia, headache, nausea, and injection site reaction. REDEMPLO is the first Health Canada–approved siRNA for FCS and is dosed by subcutaneous self-injection once every three months.

2 months ago

#ARWR Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

www.stocktitan.net/news/ARWR/arrowhead-phar...

0 0 0 0